PA-BLACK-BOX
3.11.2021 13:02:10 CET | Business Wire | Press release
Black Box, a leading global solutions integrator, announced today that it has joined with industry wireless communications innovator Nokia to provide the most complete, next-generation OnGo® private wireless/CBRS network for Industry 4.0. The partnership allows Black Box to drive innovation in connectivity and the adoption of private networks, giving the industrial manufacturing market superior options for wireless networking. Black Box explains that OnGo® — an even-licensed, low-band wireless spectrum that gives manufacturers access to private wireless connectivity at a fraction of the cost associated with LTE — mirrors the simplicity of Wi-Fi while providing secure, cost-effective LTE coverage for enterprise wireless traffic and IoT applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211103005142/en/
“Nokia welcomes Black Box to our Global Partner Program to help meet growing demand for private 4G/5G campus networks,” said Vikas Trehan, vice president, channels and alliances for Nokia. “Black Box’s intimate knowledge and trusted relationships within these enterprise campus networks, combined with world-class products and services from Nokia, will help realize the Industry 4.0 vision.”
“Private wireless and emerging private 5G networks are poised to redefine the corporate wireless networking space. Large campuses and sites like airports and large logistics and distribution hubs are pushing current WLAN standards to their technological limits,” said Bill Holman, vice president and general manager of 5G technologies at Black Box. “Thanks to our partnership with Nokia, sites like those can now break free from the limitations of WLAN and get exactly the wireless connectivity they need.”
Black Box designs, builds, and manages a full range of wireless technologies to support connected enterprise, delivering digital workplace connectivity across multiple industries. Leading manufacturers turn to Black Box to help incorporate OnGo® and 5G into their existing and future wireless networks. With Nokia Digital Automation Cloud (DAC) end-to-end private wireless, Black Box helps clients realize the full potential of Industry 4.0.
Further information about Black Box and the company’s global solutions integration services offerings is available at www.blackbox.com .
About Nokia
As a trusted partner for critical networks, we are committed to innovation and technology leadership across mobile, fixed and cloud networks with intellectual property and long-term research led by the award-winning Nokia Bell Labs. Nokia Digital Automation Cloud is a high-performance, LTE/5G end-to-end private wireless networking and edge computing platform. Delivering secure, plug and play, reliable wireless connectivity, Nokia DAC enables industrial use-cases leveraging real-time data for smart manufacturing, predictive maintenance, remote operations and Industrial Internet of Things (IoT) opportunities.
About Black Box
Black Box® is a trusted IT solutions provider delivering cutting-edge technology solutions and world-class consulting services to businesses on every continent. The breadth of our global reach and depth of expertise accelerate customer success by bringing people, ideas, and technology together to solve real-world business problems. Our IT infrastructure solutions, services, and products enable secure, flawless connectivity and meaningful collaboration across town or around the globe.
Black Box is a wholly owned subsidiary of AGC Networks. To learn more, visit the Black Box website at www.blackbox.com . Follow the company on Twitter @BlackBox_ns. Black Box® and the Double Diamond logo are registered trademarks of BB Technologies Inc.
All other trademarks referenced herein are the property of their respective owners.
PR Link: www.wallstcom.com/BlackBox/211103-Black_Box-Nokia_Partnership.docx
Photo: www.wallstcom.com/BlackBox/BlackBox-Nokia_OnGo-Private_Wireless_Network.jpg
Black Box and Nokia Team Up to Create OnGo® Private Wireless/CBRS Network for Industry 4.0
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005142/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom